17.41
-0.67
(-3.71%)
As of 1:36:33 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
358,711
358,711
310,463
331,339
391,866
Cost of Revenue
36,598
36,598
42,640
13,793
--
Gross Profit
322,113
322,113
267,823
317,546
391,866
Operating Expense
155,246
155,246
153,938
110,551
16,763
Operating Income
166,867
166,867
113,885
206,995
375,103
Net Non Operating Interest Income Expense
-3,068
-3,068
-3,339
-9,420
-17,231
Other Income Expense
-126,411
-126,411
83,552
89,374
87,404
Pretax Income
37,388
37,388
194,098
286,949
445,276
Tax Provision
13,996
13,996
14,376
66,687
76,439
Net Income Common Stockholders
23,392
23,392
179,722
213,921
265,854
Average Dilution Earnings
3,468
3,468
11,582
11,648
4,736
Diluted NI Available to Com Stockholders
26,860
26,860
191,304
225,569
270,590
Basic EPS
1.01
0.37
2.75
3.07
3.24
Diluted EPS
0.80
0.36
2.20
2.37
2.87
Basic Average Shares
62,992.25
62,726
65,435
69,644
82,062
Diluted Average Shares
68,513
74,187
86,876
95,249
94,311
Total Operating Income as Reported
--
--
--
-36,946
375,103
Total Expenses
191,844
191,844
196,578
124,344
16,763
Net Income from Continuing & Discontinued Operation
23,392
23,392
179,722
213,921
265,854
Normalized Income
60,406.39
60,406.39
169,417.28
18,569.92
260,355.52
Interest Income
19,141
19,141
15,818
6,369
1,839
Interest Expense
22,209
22,209
19,157
15,789
19,070
Net Interest Income
-3,068
-3,068
-3,339
-9,420
-17,231
EBIT
59,597
59,597
213,255
302,738
464,346
EBITDA
85,499
85,499
235,039
308,319
464,346
Reconciled Cost of Revenue
36,598
36,598
42,640
13,793
--
Reconciled Depreciation
25,902
25,902
21,784
5,581
--
Net Income from Continuing Operation Net Minority Interest
23,392
23,392
179,722
213,921
265,854
Total Unusual Items Excluding Goodwill
-59,161
-59,161
11,129
254,496
6,638
Total Unusual Items
-59,161
-59,161
11,129
254,496
6,638
Normalized EBITDA
144,660
144,660
223,910
53,823
457,708
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-22,146.61
-22,146.61
824.28
59,144.92
1,139.52
12/31/2021 - 10/5/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ARMP Armata Pharmaceuticals, Inc.
1.2900
-2.27%
FOLD Amicus Therapeutics, Inc.
7.51
-6.13%
HALO Halozyme Therapeutics, Inc.
59.75
-3.50%
TRDA Entrada Therapeutics, Inc.
7.79
-2.87%
CNTA Centessa Pharmaceuticals plc
11.67
-10.64%
HRMY Harmony Biosciences Holdings, Inc.
28.99
-6.39%
MOLN Molecular Partners AG
3.8300
+2.96%
PHGE BiomX Inc.
0.5854
-0.07%
ENTA Enanta Pharmaceuticals, Inc.
4.6002
-8.91%
PBYI Puma Biotechnology, Inc.
2.8700
-1.71%